Alkane oxidation by modified hydroxylases

US12258605B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12258605-B2
Application numberUS-202117560753-A
CountryUS
Kind codeB2
Filing dateDec 23, 2021
Priority dateMar 28, 2005
Publication dateMar 25, 2025
Grant dateMar 25, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

First claim

Opening claim text (preview).

What is claimed is: 1. An isolated or recombinant polypeptide comprising residues 456-1048 of the amino acid sequence set forth in SEQ ID NO: 1 with up to 65 conservative amino acid substitutions excluding residues 464, 631, 645, 710 and 968, wherein the amino acid sequence comprises residues selected from the group consisting of: (a) at position 464, a Z1, Z3, Z4, or Z5 amino acid residue; (b) at positions 631 and 710, a Z1 amino acid residue; (c) at position 645, a Z3 amino acid residue; and (d) at position 968, a Z2 amino acid residue, wherein: Z1 is an amino acid residue selected from the group consisting of glycine (G), asparagine (N), glutamine (Q), serine(S), threonine (T), tyrosine (Y), and cysteine (C); Z2 is an amino acid residue selected from the group consisting of alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), and methionine (M); Z3 is an amino acid residue selected from the group consisting of lysine (K), and arginine (R); Z4 is an amino acid residue selected from the group consisting of tyrosine (Y), phenylalanine (F), tryptophan (W), and histidine (H); and is an amino acid residue selected from the group consisting of threonine (T), valine (V), and isoleucine (I), wherein when the isolated or recombinant polypeptide is operably linked to the heme domain of a cytochrome P450 enzyme to form a chimeric polypeptide the chimeric polypeptide has cytochrome P450 activity. 2. The polypeptide of claim 1 , comprising up to 40 conservative amino acid substitutions excluding residues 464, 631, 645, 710 and 968 of SEQ ID NO: 1. 3. The polypeptide of claim 1 , comprising up to 25 conservative amino acid substitutions excluding residues 464, 631, 645, 710 and 968 of SEQ ID NO: 1. 4. The polypeptide of claim 1 , comprising up to 10 conservative amino acid substitutions excluding residues 464, 631, 645, 710 and 968 of SEQ ID NO: 1. 5. The polypeptide of claim 1 , wherein the amino acid sequence comprises residues selected from the group consisting of: (a) at position 464, a glycine (G), arginine (R), tyrosine (Y), or threonine (T) amino acid residue; (b) at position 631, an asparagine (N) amino acid residue; (c) at position 645, an arginine (R) amino acid residue; (d) at position 710, a threonine (T) amino acid residue; and (e) at position 968, a lysine (L) amino acid residue. 6. The polypeptide of claim 1 , comprising up to 50 conservative amino acid substitutions excluding residues 464, 631, 645, 710 and 968 of SEQ ID NO:1. 7. A chimeric polypeptide comprising the isolated or recombinant polypeptide of claim 1 , operably linked to a heme catalytic domain, wherein the chimeric polypeptide has cytochrome P450 activity. 8. The chimeric polypeptide of claim 7 , wherein the heme catalytic domain is from a species different than the isolated or recombinant polypeptide.

Assignees

Inventors

Classifications

  • Biofuels, e.g. bio-diesel · CPC title

  • Alkane 1-monooxygenase (1.14.15.3) · CPC title

  • with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15) · CPC title

  • Unspecific monooxygenase (1.14.14.1) · CPC title

  • NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12258605B2 cover?
This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.
Who is the assignee on this patent?
The California Institute Of Tech, California Inst Of Techn
What technology area does this patent fall under?
Primary CPC classification C12P7/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).